为您找到相关结果约56个

你是不是要搜索 期刊Opdivo 点击跳转

OPDIVO (R) - The new Standard in Second-Line Therapy

MELANOMA OPDIVO (R) + YERVOY (R) Combination: Impressive Efficacy in Melanoma

OPDIVO (R) in Urology is now approved for two Tumor Entities

OPDIVO (R) plus YERVOY (R): Paradigm Shift in the Treatment of Brain Metastases

- Learnings from Keytruda and Opdivo

Head-Neck-Tumors OPDIVO (R) gets Approval for Head and Neck Tumors

Bristol Myers Squibb receives CHMP Approval Recommendation for Nivolumab (Opdivo((R)))/Advanced ESCC

ACUTE AUTOIMMUNE MYASTENIC SYNDROME AND RHABDOMYOLYSIS AFTER NIVOLUMAB (OPDIVO) TO TREAT ADVANCED NSC

Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo

Clinical and economic analysis of effectiveness of Nivolumab (Opdivo((R))) use as second-line monotherapy

Clinical and economic analysis of effectiveness of Nivolumab (Opdivo @) use as second-line monotherapy

extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo

Bristol Myers Squibb receives European Commission approval for Nivolumab (Opdivo (R)) in Combination

Bristol Myers Squibb receives CHMP Approval Recommendation for Nivolumab (Opdivo®) plus Chemotherapy

Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress

为您找到相关结果约56个

共56条页码: 1/4页15条/页